Co-culture of placental stem cells and stem cells from a second source
View Patent ↗The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.
1. A method of identifying a ratio of placental stem cells to stem cells from a second source, comprising combining and culturing a number of placental stem cells and a number of stem cells from a second source in a plurality of ratios for a time and under conditions sufficient to allow colony-forming units to form, and identifying the ratio in said plurality of ratios that produces a greater number of colony-forming units than a number of placental stem cells or stem cells from the second source, equivalent to the total number of placental stem cells and stem cells from the second source, alone, and produces the highest number of colony-forming units in said plurality of ratios.
2. The method of claim 1 , wherein said placental stem cells are derived from a single placenta.
3. The method of claim 1 , wherein said placental stem cells are derived from a plurality of placentas.
4. The method of claim 1 , wherein said placental stem cells are stem cells from placental perfusate.
5. The method of claim 1 , wherein said stem cells from the second source are cord blood-derived stem cells.
6. The method of claim 5 , wherein said cord blood-derived stem cells are hematopoietic stem cells.
7. The method of claim 1 , wherein said placental stem cells and the stem cells from the second source are combined in a suspension.
8. The method of claim 7 additionally comprising adding to said suspension a bioactive molecule.
9. The method of claim 8 , wherein said bioactive molecule is a cytokine or a growth factor.
10. The method of claim 1 , wherein said placental stem cells are obtained from a single individual.
11. The method of claim 1 , wherein said placental stem cells are obtained from a plurality of individuals.
12. The method of claim 1 , wherein said placental stem cells are CD34 − and not trophoblasts.
13. The method of claim 12 , wherein said placental stem cells are CD34 − , CD10 + , CD105 + (SH2 + ) and CD200 + .
14. The method of claim 13 , wherein said placental stem cells are additionally CD45 − and CD90 + .
15. The method of claim 1 , wherein said stem cells from the second source are hematopoietic stem cells.
16. The method of claim 15 , wherein said hematopoietic stem cells from the second source are CD34 + .
17. The method of claim 16 , wherein said CD34 + cells are isolated from umbilical cord blood (UCB).
18. The method of claim 16 , wherein said CD34 + cells are contained within UCB.